CAS: 997-20-6; (S)-6-Amino-2-((S)-6-Amino-2-((S)-6-Amino-2-((S)-2,6-Diaminohexanamido)Hexanamido)Hexanamido)Hexanoic Acid

上下游产品

L-lysine ethyl ester dihydr°Chloride L-lysine n-butyl ester di-p-toluene sulfonate L-lysine n-hexyl ester di-p-toluene sulfonate L-glutamic acid

📜Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于盐酸,Palladium On Activated Charcoal体系中,化学反应生成 四聚赖氨酸
参考文献:95.赖氨酸的一些肽
标题:95.赖氨酸的一些肽
摘要:
DOI:10.1039/jr9530000475

专利信息

专利号:US-9567430-B2
优先权日:2011-12-02
标 题 :Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
发明人：SALTZMAN W MARK; JIANG ZHAOZHONG; ZHOU JIANGBING; LIU JIE
权利人:UNIV YALE
摘要:Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticles are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.

专利号:WO-2013082529-A1
优先权日:2011-12-02
标题 :Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
发明人：SALTZMAN W MARK; JIANG ZHAOZHONG; ZHOU JIANGBING
权利人:UNIV YALE
摘要:Poly(amine-co-ester) polymers, methods of forming active agent-load nanoparticies therefrom, and methods of using the nanoparticies for drug delivery are disclosed. The nanoparticies can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticies are less toxic, more efficient at drug delivery, or a combination thereof compared to a control other transfection reagents. In some embodiments, the nanoparticies are suitable for in vivo delivery, and can be administered systemically to a subject to treat a disease or condition.

专利号:US-6825339-B2
优先权日:1993-12-16
标题:Apparatus for preparing polynucleotides on a solid support
发明人：CHATELAIN FRANCOIS; KUMAREV VIKTOR
权利人:PROLIGO LLC
摘要:The present invention relates to an apparatus for preparing polynucleotides on a solid support in a reactor comprising a column containing an immobilized solid support that is functionalized for polynucleotide synthesis. The solid support can be porous, and can be functionalized with a nucleoside or with a universal synthesis of polynucleotides.

专利号:US-2008051323-A1
优先权日:2004-08-21
标 题 :Chloroquine drug compositions and methods for their synthesis
发明人：KOSAK KENNETH M
权利人:KOSAK KENNETH M
摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. n The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

专利号:US-2007060499-A1
优先权日:2005-09-15
标 题 :Chloroquine combination drugs and methods for their synthesis
发明人：KOSAK KENNETH M
权利人:KOSAK KENNETH M
摘要:This invention discloses compositions of chloroquine-coupled active agents, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the active agent is delivered, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to an active agent directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing active agents for therapeutic or other medical uses. The invention also discloses carrier compositions that are coupled to targeting molecules for targeting the delivery of chloroquine substances and active agents to their site of action.

专利号:WO-9503408-A1
优先权日:1993-07-26
标 题:B7-2: ctl a4/cd 28 counter receptor
发明人：FREEMAN GORDON J; NADLER LEE M; GRAY GARY S; GREENFIELD EDWARD
权利人:DANA FARBER CANCER INST INC; REPLIGEN CORP
摘要:Nucleic acids encoding novel CTLA4/CD28 ligands which costimulate T cell activation are disclosed. In one embodiment, the nucleic acid has a sequence which encodes a B lymphocyte antigen, B7-2. Preferably, the nucleic acid is a DNA molecule comprising at least a portion of a nucleotide sequence shown in Figure 8, SEQ ID NO: 1 or Figure 14, SEQ ID NO: 23. The nucleic acid sequences of the invention can be integrated into various expression vectors, which in turn direct the synthesis of the corresponding proteins or peptides in a variety of hosts, particularly eukaryotic cells, such as mammalian and insect cell culture. Also disclosed are host cells transformed to produce proteins or peptides encoded by the nucleic acid sequences of the invention and isolated proteins and peptides which comprise at least a portion of a novel B lymphocyte antigen. Proteins and peptides described herein can be administered to subjects to enhance or suppress T cell-mediated immune responses.